‘The Theranos fiasco’ didn’t stop Group K Diagnostics from raising $800,000

Written by By Roberto Torres, Technical.ly Philly

“I walked into a meeting with investors and I happened to be wearing a black sweater,” said Group K CEO Brianna Wronko. “They asked if I was the new Elizabeth Holmes.”

An $800,000 angel round, funded by a mix of private and institutional investors, will let Group K Diagnostics expand its team and fuel clinical trials for its point-of-care diagnostics tool.

The funding, CEO and founder Brianna Wronko said, will help Group K evaluate its liver-function testing device in a clinical trial setting, as well as advance the work needed to obtain a 510(k) clearance from the Food and Drug Administration.

Read more.